Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Schlumberger NV (SLB) Price & Performance

Abeona Therapeutics IncTrade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Schlumberger NV — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Schlumberger NV trades at $52.91 (market cap $79.67B). The key difference: Schlumberger NV is far larger — about 189.2× Abeona Therapeutics Inc's market cap, and Schlumberger NV pays a 2.2% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOSLB
Market Cap
$421.19M$79.67B
Sector
HealthEnergy
52-Week High
$7.45$58.01
52-Week Low
$4.17$31.72
Enterprise Value
$276.10M$88.40B
Dividend Yield
2.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Schlumberger NV

SLB trades at $53.20, up 5.28% over the past day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.55 versus $0.511 expected, driven by digital and production growth. Revenue for 2025 was $35.71 billion, with net income of $3.37 billion, though margins have compressed from prior years. The stock shows robust institutional support and positive media sentiment following upbeat results.

Outlook remains positive with a consensus price target of $63.00, implying 18% upside, supported by offshore and digital expansion. Risks include Middle East volatility and net debt concerns. The dividend yield is modest at around 1.1%, with the next payment scheduled for October 2026. Investors should weigh growth catalysts against regional and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB